- Home
- BXC vs PHAR Comparison
BXC vs PHAR Comparison
Compare BXC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXC
- PHAR
- Stock Information
- Founded
- BXC 2004
- PHAR 1988
- Country
- BXC United States
- PHAR Netherlands
- Employees
- BXC N/A
- PHAR N/A
- Industry
- BXC Wholesale Distributors
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- BXC Consumer Discretionary
- PHAR Health Care
- Exchange
- BXC Nasdaq
- PHAR Nasdaq
- Market Cap
- BXC 663.8M
- PHAR 587.5M
- IPO Year
- BXC 2004
- PHAR N/A
- Fundamental
- Price
- BXC $71.94
- PHAR N/A
- Analyst Decision
- BXC Strong Buy
- PHAR Strong Buy
- Analyst Count
- BXC 5
- PHAR 3
- Target Price
- BXC $125.20
- PHAR $30.00
- AVG Volume (30 Days)
- BXC 107.0K
- PHAR 4.6K
- Earning Date
- BXC 04-29-2025
- PHAR 05-08-2025
- Dividend Yield
- BXC N/A
- PHAR N/A
- EPS Growth
- BXC 14.84
- PHAR N/A
- EPS
- BXC 6.19
- PHAR N/A
- Revenue
- BXC $2,952,532,000.00
- PHAR $297,200,000.00
- Revenue This Year
- BXC $4.52
- PHAR $8.26
- Revenue Next Year
- BXC $5.77
- PHAR $9.73
- P/E Ratio
- BXC $11.62
- PHAR N/A
- Revenue Growth
- BXC N/A
- PHAR 21.15
- 52 Week Low
- BXC $67.42
- PHAR $6.65
- 52 Week High
- BXC $134.79
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- BXC 41.60
- PHAR 45.53
- Support Level
- BXC $68.70
- PHAR $7.79
- Resistance Level
- BXC $72.91
- PHAR $8.51
- Average True Range (ATR)
- BXC 4.21
- PHAR 0.47
- MACD
- BXC 0.19
- PHAR 0.01
- Stochastic Oscillator
- BXC 42.09
- PHAR 49.08
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.